Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in this clinical trial publication.

A total of 5 7 treatment courses were initiated for induction of spermatogenesis, 36 of these for the purpose of induction of pregnancy in the female partner.

Why It Was Studied

However, there is still uncertainty about the optimal treatment modality and schedule, the duration of treatment necessary and the influence of interfering factors such as maldescended testes.

The researchers have extended their previous series of men treated for secondary hypogonadism and now present their therapeutic experience with 42 cases.

Who Took Part

According to the abstract, 21 patients were involved.

PubMed indexes the participants as adults, both men and women.

Twenty-one patients with hypothalamic disorders (11 with idiopathic hypogonadotropic hypogonadism (IHH) and 10 with Kallmann syndrome (KalS)) were treated with GnRH (group Ia) or human chorionic gonadotropin (hCG)/human menopausal gonadotropin (hMG) (group Ib), and 21 patients with hypopituitarism (group II) were treated with hCG/hMG.

What Was Measured

However, there is still uncertainty about the optimal treatment modality and schedule, the duration of treatment necessary and the influence of interfering factors such as maldescended testes.

The researchers have extended their previous series of men treated for secondary hypogonadism and now present their therapeutic experience with 42 cases.

The subject headings attached to it are Chorionic Gonadotropin, Fertility, Gonadotropin-Releasing Hormone, Hypogonadism, Menotropins, Spermatogenesis and Testis.

What This Means in Plain Language

This is a clinical trial of hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in 21 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (European journal of endocrinology), a journal based in England.

More context: the hCG (human chorionic gonadotropin) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.